Cizzle Biotechnology Holdings Plc
CIZ.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 40.42 | 0.05 | -0.01 |
| FCF Yield | -5,960.81% | -9.21% | -20.64% | -25.11% |
| EV / EBITDA | 0.00 | 0.00 | -3.89 | -1.00 |
| Quality | ||||
| ROIC | -1,060.45% | -63.07% | -34.55% | -89.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.16 | 0.36 | 0.91 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 43.97% | 26.72% | 27.87% | -311.22% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.50 | 0.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |